Introduction: Evaluating the Safety of Hormone Replacement Therapy

A recent Danish study on the implications of hormone replacement therapy (HRT) initiated soon after menopause has instigated a new debate within the scientific community concerning the treatment's cancer risk. Contrary to previous studies, this research suggests that women who begin HRT within 16 years of menopause do not present a heightened incidence of cancer.

Post-Menopause HRT and a Lower Risk of Death or Heart Complications
Published on the medical website bmj.com, the study reveals that women who undertook HRT displayed a significantly reduced risk of death or developing heart complications. While this study echoes the sentiments of a menopause awareness community, it has been criticized for being underpowered by a researcher who led a broader foray into the effects of HRT.

Controversy Surrounding HRT
Since a 2002 research study by the Women's Health Initiative (WHI) reported an elevated risk of breast cancer for women undergoing HRT, this treatment has been shrouded in controversy. The findings were reinforced by the Million Women Study (MWS) a year later, further complicating perceptions of HRT. The Danish team's research suggesting a significant reduction in death, heart failure, or myocardial infarction (heart attack) for women starting HRT early in postmenopause challenges the conventional understanding of HRT. Moreover, they found no increased risks of cancer, stroke, deep vein thrombosis, or pulmonary embolism associated with the usage of HRT.

Evaluating the Increased Risk of Cancer from HRT
The MWS caused significant concern when it reported that HRT could potentially increase cancer risk by between 30 to 100 percent. This claim was met with skepticism from some scientific quarters who questioned the study method's soundness. HRT, which employs the female hormones estrogen or progestogen, sometimes in combination, aims to alleviate menopausal symptoms such as hot flashes, loss of sex drive, and vaginal dryness.

Study Parameters and Participant Demographics
The Danish study analyzed 1,006 recently postmenopausal women, with half receiving HRT and the others receiving no treatment. Aside from the HRT group being slightly older by 5.7 months, no other significant discrepancies regarding parameters such as weight, health, or smoking habits were presented between the two groups.

References:
1. Study stokes new debate over cancer risk
2. Hormone therapy 'not a cancer risk', new study finds

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.